Methestrol

Clinical data
Trade names	Meprane
Other names	Methoestrol; Metestrol; Promethestrol; Promethoestrol; Dimethylhexestrol
Drug class	Nonsteroidal estrogen
Identifiers
IUPAC name 4-[4-(4-hydroxy-3-methylphenyl)hexan-3-yl]-2-methylphenol
CAS Number	130-73-4
PubChem CID	71620
ChemSpider	64688
UNII	199O25Z2BQ
CompTox Dashboard (EPA)	DTXSID90861783
Chemical and physical data
Formula	C20H26O2
Molar mass	298.426 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCC(C1=CC(=C(C=C1)O)C)C(CC)C2=CC(=C(C=C2)O)C
InChI InChI=1S/C20H26O2/c1-5-17(15-7-9-19(21)13(3)11-15)18(6-2)16-8-10-20(22)14(4)12-16/h7-12,17-18,21-22H,5-6H2,1-4H3 Key:PYWBJEDBESDHNP-UHFFFAOYSA-N

Methestrol (INNTooltip International Nonproprietary Name; brand name Meprane) or methoestrol, also known as promethestrol or promethoestrol (BANTooltip British Approved Name) or as dimethylhexestrol, is a synthetic nonsteroidal estrogen of the stilbestrol group related to diethylstilbestrol which is no longer marketed.^{[1][2][3][4][5][6][7]}

A related drug is methestrol dipropionate (or promethestrol dipropionate) (brand name Meprane Dipropionate).^{[8][9][10][11][12][13]}

1. ^ Ganellin CR, Triggle DJ (21 November 1996). Dictionary of Pharmacological Agents. CRC Press. pp. 608–. ISBN 978-0-412-46630-4.
2. ^ Brucker MC, King TL (8 September 2015). Pharmacology for Women's Health. Jones & Bartlett Learning. pp. 640–. ISBN 978-1-284-10811-8.
3. ^ Sturgis SH (April 1947). "Preliminary clinical report on a new synthetic estrogen, meprane". American Journal of Obstetrics and Gynecology. 53 (4): 678–681. doi:10.1016/0002-9378(47)90289-5. PMID 20291241.
4. ^ Coulton D (August 1947). "Meprane an effective estrogen for inhibition and suppression of lactation". American Journal of Obstetrics and Gynecology. 54 (2): 289–295. doi:10.1016/s0002-9378(16)39536-9. PMID 20257315.
5. ^ Coulton D, Sewall CW (September 1948). "Meprane in the treatment of the menopausal syndrome; an evaluation of estrogenic efficiency and toxicity". American Journal of Obstetrics and Gynecology. 56 (3): 541–548. doi:10.1016/0002-9378(48)90643-7. PMID 18877188.
6. ^ Lin HA (August 1947). "A clinical study of a new synthetic estrogen". American Journal of Obstetrics and Gynecology. 54 (2): 296–300. doi:10.1016/s0002-9378(16)39537-0. PMID 20257316.
7. ^ Jones GF (November 1949). "Physiology and management of the climacteric". California Medicine. 71 (5): 345–348. PMC 1520053. PMID 15390574.
8. ^ Ganellin CR, Triggle DJ (21 November 1996). Dictionary of Pharmacological Agents. Taylor & Francis. pp. 1298–. ISBN 978-0-412-46630-4.
9. ^ Thomas JA, Keenan EJ (6 December 2012). "Estrogens and Antiestrogenic Drug". Principles of Endocrine Pharmacology. Springer Science & Business Media. pp. 150–. ISBN 978-1-4684-5036-1.
10. ^ "Female Reprodiction – Ovary". Essential of Endocrinology and Reproductive Physiology. Allied Publishers. 1985. pp. 85–. GGKEY:HLNJ1BHUKW2.
11. ^ Modell W (21 November 2013). Drugs in Current Use 1958. Springer. pp. 114–. ISBN 978-3-662-40303-7.
12. ^ Dubin (6 December 2012). Emergency Psychiatry for the House Officer. Springer Science & Business Media. pp. 155–. ISBN 978-94-011-6690-4.
13. ^ Forsberg JG (22 October 2013). "Induction of Conditions Leading to Cancer in the Genital Tract by Estrogen During the Differentiation Phase of the Genital Epithelium". In Raspé G (ed.). Hormones and Embryonic Development: Advances in The Biosciences. Elsevier Science. pp. 141–. ISBN 978-1-4831-5171-7.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by adding missing information.

• v
• t
• e